CD47 and neoplasm: Interestingly, we found that the combination of NextA and anti-CD47 decreased tumor growth in SM1 melanoma-bearing mice, increased total immune cell infiltration in the TME, and altered the immune cell composition compared to the single treatment arms, mostly modulating macrophages and NK cells (Fig. 5).